Tag Archives: Lung Cancer

Gold Nano Particles May Boost Lung Cancer Treatment

Gold Nano-particles Can be Introduced into the Bloodstream to Help Fight Cancer.
Gold Nano-particles Can be Introduced into the Bloodstream to Help Fight Cancer.

Gold may have a value that goes well beyond financial gain. Researchers have discovered that the shiny element can enhance the effectiveness of drugs used to treat lung cancer.

Cancer Treatment as Good as Gold

Testing was conducted at the University of Edinburgh, where Scientists took nanoparticles, which are microscopic particles of gold, and encased them in a chemical device. The object was then used on zebrafish to successfully accelerate their chemical reactions.

Dr. Asier Unciti-Broceta from Cancer Research U.K.’s Edinburgh center participated in the study. He explained that the team’s goal was to find a way to reduce side effects of current chemotherapy methods.

Lessening the Side Effects of Traditional Cancer Treatment

Side effects of cancer treatment are usually the result of drugs attacking healthy cells as well as diseased ones. According to Dr. Unciti-Broceta, their findings indicate that gold could possibly be used to safely release drugs inside tumors.

Immunotherapy for cancer is effective because it helps the immune system’s ability to target cancer cells while sparing healthy tissue. Researchers are continuing tests with nanoparticles in the hopes of applying a similar method with humans.

Dr. Aine McCarthy, also of Cancer Research U.K., expressed optimism that incorporating gold in immunotherapy for cancer could improve the outlook for hard-to-treat cancers such as brain tumors.

Issels®: The Gold Standard of Immunotherapy for Cancer

Our integrative cancer treatment programs are personally tailored for each patient to include methods that complement each other for maximum effectiveness. Contact us today to learn more about our distinguished history of treating patients with all forms of cancer.

Medicare Coverage for Early Detection of Cancer – What to Know

Medicare Coverage for Early Detection of Cancer - What to Know
Medicare Coverage for Early Detection of Cancer – What to Know

Navigating the ins and outs of Medicare coverage can be a challenge. Here’s what you need to know about this program and how it applies to screenings for early detection of cancer.

Do All Providers Accept Medicare?

• Participating doctors “accept assignments,” meaning they consider the amount received from Medicare along with your co-pay and deductible as payment in full, resulting in fewer out-of-pocket expenses.

• Non-participating doctors don’t always accept Medicare, so you have to pay out-of-pocket. Medicare will reimburse you for the portions they normally cover, but you still incur sizable expenses for the difference.

• Opt-out doctors don’t participate in Medicare at all, making you fully responsible for all charges.

Medicare Coverage for Cancer Screening

• Annual mammograms are covered for women aged 40 and older, while clinical breast exams (CBE) are covered every two years for women at average risk for breast cancer and once a year for those at high risk.

• Women at average risk for cervical cancer are covered for a Pap test and pelvis exam every two years, while women at high risk are covered annually.

• Colorectal screening is covered for people 50 and over based on risk factors and date of last test.

• For prostate screening, men over age 50 are covered 100 percent for an annual PSA blood test and 80 percent for a digital rectal exam (DRE).

Lung cancer screening is covered once a year if you are between 55 and 77 and have a qualifying history of smoking.

State-of-the-Art Cancer Treatment at Issels®

Our personalized cancer treatment programs have helped many of our patients achieve long-term remission. Visit our website for more information.

Study Finds that Older Lung Cancer Patients May Still Benefit from Surgery

Lung Cancer
Lung Cancer

Lung cancer is the second most common form of cancer in both men and women, and nearly all the patients are over the age of 45. Despite the fact that the average age of diagnosis is 70, cancer surgery is proving to be a viable treatment option that can extend the lives of these patients.

Is Surgery Appropriate for Older Patients?

The general opinion, even among healthcare professionals, is that surgery is too hard on the aging bodies of older patients to be considered as a solution for lung cancer. Treatment then focuses on controlling the symptoms rather than attempting curative solutions.

Evaluating Surgical Treatment for Lung Cancer

In October 2016 the Journal of Clinical Oncology published a study headed up by Dr. Prasad Adusumilli, a thoracic surgeon at Memorial Sloan Kettering Cancer Center in New York. Participants included more than 2,000 patients diagnosed with Stage 1 non-small cell lung cancer. Approximately 70 percent of the subjects were 65 or older.

After these patients had surgery to remove the tumors, the group experienced a remarkable track record of success. The first year follow-up showed that patient deaths to that point were most often due to causes other than lung cancer. Even more encouraging news was that after five years nearly 90 percent of the patients were alive and cancer-free.

Instead of Surgery Consider Immunotherapy for Cancer

At Issels®, our personally tailored immunotherapy for cancer treatments are designed to boost your body’s natural defenses against the disease. Contact us to learn more about state-of-the-art non-surgical programs such as cancer vaccines and cell therapies prepared from your own immune cells.

Incidence of Lung Cancer in Non-Smokers Rises to 15%

Lung Cancer On The Decline
Rise in Lung Cancer in Non Smokers

Smoking tobacco has long been a known risk factor for lung cancer. Surprisingly, as smoking rates have declined, non-smokers have accounted for a higher percentage of lung cancer cases. In addition, these patients are more likely to be women.

Data comes from studies in Great Britain and the United States involving non-small cell cancer, which constitutes 85 to 90 percent of all lung cancer cases. This type is aggressive and usually detected at a later stage, particularly in non-smokers who are not screened as often due to fewer risk factors.

Over a seven-year period, British researchers discovered that the percentage of never-smokers with lung cancer more than doubled from 13 percent to 28 percent. Subjects included 2,170 patients between 2008 and 2014.

Their American counterparts had similar results in a study of lung cancer patients between 1990 and 2013. According to lead researcher Dr. Lorraine Pelosof, nine percent of non-small cell patients between 1990 and 1995 were never-smokers. In the period of 2011-2013, the percentage had grown to nearly 15 percent.

At present, researchers are stumped as to the reason for these increases, or why women are more susceptible. Ongoing studies are focusing on genetic risk and family history as possible causes in the absence of tobacco use. Dr. Pelosof also commented on the need to confirm her team’s findings, noting limitations such as the smoking history of subjects being self-reported.

Our Issels® immuno-oncology protocols take into account your lifestyle, genetic history, environment and other factors that affect your case. The result is a personalized, non-toxic course of treatment that addresses your specific needs. Visit our website to learn more.

New Research: Melanoma Drug Causes Decrease in Lung Cancer Tumors

Lung Cancer On The Decline
Fighting Lung Cancer With Skin Cancer Drugs

At our Issels® Integrative Immuno-Oncology centers, we treat a wide variety of cancers including lung cancer. As previously mentioned, we offer this blog to give patients, caregivers, doctors, researchers, educators and students as much information as possible about new, beneficial immunotherapy advances that we feel can help patients.

As reported in May in the New England Journal of Medicine, a recent study found that nivolumab (Opdivo), a new immune checkpoint inhibitor drug that reveals cancer cells that pretend to be healthy cells to help push the immune system to destroy the cancer, is stopping the spread of melanoma and lung cancers almost two times better than ipilimumab (Yervoy).

Side Effects

Side effects with all immunotherapy drug treatments continue to be a problem for as many as 70 to 80 percent of patients. These two drugs were no different. Both caused side effects and the effects increased when the drugs were tested in combination.

Positive Outcomes

Researchers believe the outstanding results outweigh any side effects given there were no deaths during a trial that focused on 945 patients who had advanced and untreated melanoma. Best yet:

  • Patients who received nivolumab experienced a 7-month disease slowdown and a 34 percent tumor reduction versus a 3-month ipilimumab slowdown and 6 percent tumor reduction.
  • Combining both drugs resulted in a 11.5-month slowdown and a 52-percent reduction.

We believe at Issels® that the discovery of nivolumab (Opdivo) as a lung cancer treatment option, and the discovery of the higher effectiveness of the drug when used in combination with ipilimumab (Yervoy), represent incredible breakthroughs in immunotherapy and non-toxic treatment solutions. Contact us today for more information or to schedule an appointment.

Lung Cancer Grows in Women and May Surpass Breast Cancer

Lung Cancer On The Decline
Lung Cancer In Women

Breast cancer can rightly be considered the most significant disease facing women specifically. However, researchers have long warned that lung cancer rates could overtake breast cancer as the most fatal form of the disease in women. The Annals of Oncology have recently released a report confirming that 2015 may be the year that lung cancer kills more women than breast cancer across Europe.

Even while cancer death rates decline overall, lung cancer rates trend upward as the population ages. The statistics in Europe reflect a global truth: where smoking has been prevalent, both men and women face high rates of lung cancer.

The fact that this disease could affect more women than breast cancer serves as a reminder for necessity of awareness and prevention efforts.

There are several key issues to understand about the rise of lung cancer in women:

  • Many women began smoking after World War II. As the population ages, more women develop lung cancer. Smoking cessation can begin to reduce the rates.
  • Rates vary notably by country. Smoking has been more common in England and Poland than many other European countries. British women (21 per 100,000) and Polish women (17 per 100,000) exceed the EU average of 14 deaths per 100,000.
  • The trends represent a rise in lung cancer rates, more than a reduction in breast cancer rates.

At Issels® Integrative Immuno-Oncology, we study every case of cancer individually. Research into the overall trends provides another important facet of fighting cancer: if we understand why one form of the disease is becoming more common, we can better anticipate future patient needs. Contact Issels® to find out about holistic and individualized cancer therapies.